Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472142 | 0.92 | GFER (0.55) | EPHX2GFERNPC1TDP1TAAR1 | |
| SCHEMBL2469409 | 0.92 | GFER (0.55) | EPHX2GFERNPC1TDP1TAAR1 | |
| SCHEMBL2472152 | 0.91 | NPC1 (0.55) | EPHX2ALDH1A1GFERNPC1TDP1 | |
| SCHEMBL2472451 | 0.88 | NPC1 (0.46) | ALDH1A1NPC1TDP1USP7KMT2A | |
| SCHEMBL2471243 | 0.87 | PLAAT3 (0.46) | OPRM1OPRD1ALDH1A1NPC1TDP1 | |
| SCHEMBL2470199 | 0.87 | GFER (0.50) | EPHX2ALDH1A1GFERNPC1TDP1 | |
| SCHEMBL2469442 | 0.86 | PLAAT3 (0.55) | EPHX2ALDH1A1NPC1TDP1KMT2A | |
| SCHEMBL2471555 | 0.86 | NPC1 (0.45) | ALDH1A1NPC1TDP1USP7KMT2A | |
| SCHEMBL2471161 | 0.85 | ALDH1A1 (0.55) | EPHX2ALDH1A1NPC1TDP1USP7 | |
| SCHEMBL2495227 | 0.85 | NPC1 (0.49) | ALDH1A1NPC1TDP1USP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | OPRM1 2850/4885OPRD1 2240/4885EPHX2 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.